BRIEF—Another Humira biosimilar approved in Europe

Copycat specialist Mylan and joint venture Fujifilm Kyowa Kirin Biologics have won approval in Europe for Hulio, the firms' biosimilar version of AbbVie’s Humira (adalimumab), for all indications.

Japanese firms Fujifilm and Kyowa Hakko Kirin launched their JV for the development, manufacturing and sales of biosimilars in 2012.

The product will be marketed by Fujifilm Kyowa Kirin Biologics in Europe, under the terms of a licensing agreement.

Mylan president Rajiv Malik said: “This is the fourth product that Mylan will be bringing to market in the area of complex generics and biosimilars,” adding “We’ve made great progress with Fujifilm Kyowa Kirin Biologics and look forward to continuing this important collaboration.”